Skip to main content
Premium Trial:

Request an Annual Quote

Solexa Secures Remaining $24M of $32.5M Private Equity Financing from April

NEW YORK, July 14 (GenomeWeb News) - Solexa has secured the remaining $24 million in the second closing of its $32.5 million private equity financing, the company said on Tuesday.

 

The first closing of the funding round, completed in April, generated proceeds of $8.5 million from the sale of 2.1 million shares of common stock and 1.1 million warrants.

 

Under the terms of the second closing, Solexa raised $24 million by selling 6 million shares of common stock at $4 per share and issuing warrants to purchase up to 3 million shares of common stock at an exercise price of $5 per share.

 

The financing round was led by ValueAct Capital of San Francisco. Solexa's previous investors, Abingworth Management, Amadeus Capital Partners, Oxford Bioscience Partners, and SV Life Sciences invested $10.8 million in total at the second closing.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.